Seifert-Klauss, V., & Prior, J. C. (2010). Progesterone and bone: actions promoting bone health in women. Journal of Osteoporosis, 2010, 845180. https://doi.org/10.4061/2010/845180
Seifert-Klauss V, Prior JC. Progesterone and bone: actions promoting bone health in women. J Osteoporos. 2010;2010:845180. doi:10.4061/2010/845180
Seifert-Klauss, Vanadin, and Jerilynn C. Prior. "Progesterone and bone: actions promoting bone health in women." Journal of Osteoporosis, vol. 2010, 2010, pp. 845180.
For EndNote, Zotero or Mendeley:
Open access
No open license is recorded for this paper. Reuse terms are set by the publisher.
Vancouver Hospital and Health Sciences Centre05p83my93
Linked to ROR, the Research Organization Registry
RRM Academy Synopsis
Progesterone may protect bone in premenopausal women, a review finds
A 2010 review concludes that cyclic progestin stops bone loss in healthy younger women with absent periods or disturbed ovulation. A 61-woman randomized trial supports this. Five pooled cohorts of 458 women link ovulatory disturbances to bone loss. In four placebo-controlled trials of postmenopausal women with raised bone turnover, progesterone did not stop bone loss.
Key Findings
Five prospective cohort studies followed 458 healthy premenopausal women for one to four years and examined ovulatory disturbances alongside bone density change.
In three studies with at least five documented cycles a year, women with mostly normal ovulation had a +1.23% bone density change a year. Women with ovulatory disturbances had −1.00% a year.
In 61 women with ovulatory disturbances or amenorrhea, cyclic medroxyprogesterone raised spine bone density by +1.7% over one year. Women on double placebo changed by −2.0% (P = .005).
In placebo-controlled trials of postmenopausal women, bone change was −2.2% a year on progestin or progesterone and −2.4% a year on placebo.
In five randomized trials of postmenopausal women with osteoporosis, medroxyprogesterone plus an antiresorptive gave a mean spine change of +1.7% a year, against +1.3% a year for the antiresorptive alone.
Interpretation
The review combines observational cohorts with randomized trials. These are a 61-woman trial of cyclic medroxyprogesterone, four placebo-controlled trials in postmenopausal women and five co-therapy trials. The cohorts show an association between ovulatory disturbances and bone loss. The authors say studies with under five documented cycles a year could not detect it. Participants in the five premenopausal cohorts were mostly white, well-educated women in their 30s. The authors report that fracture data for progesterone are lacking.
RRM Context
Fertility awareness charting records when ovulation happens. In the cohorts, basal temperature charts showed how long the luteal phase lasted. Ovulation problems occurred in regular cycles with normal estrogen, and these were linked with bone loss. Estradiol slows bone breakdown while progesterone supports bone building.
Our editorial summary of this paper, not the article's abstract.
Abstract
Estradiol (E(2)) and progesterone (P(4)) collaborate within bone remodelling on resorption (E(2)) and formation (P(4)). We integrate evidence that P(4) may prevent and, with antiresorptives, treat women's osteoporosis. P(4) stimulates osteoblast differentiation in vitro. Menarche (E(2)) and onset of ovulation (P(4)) both contribute to peak BMD. Meta-analysis of 5 studies confirms that regularly cycling premenopausal women lose bone mineral density (BMD) related to subclinical ovulatory disturbances (SODs). Cyclic progestin prevents bone loss in healthy premenopausal women with amenorrhea or SOD. BMD loss is more rapid in perimenopause than postmenopause-decreased bone formation due to P(4) deficiency contributes. In 4 placebo-controlled RCTs, BMD loss is not prevented by P(4) in postmenopausal women with increased bone turnover. However, 5 studies of E(2)-MPA co-therapy show greater BMD increases versus E(2) alone. P(4) fracture data are lacking. P(4) prevents bone loss in pre- and possibly perimenopausal women; progesterone co-therapy with antiresorptives may increase bone formation and BMD.
Bone Health › Hormones and Bone › Estrogen and Bone · Therapeutics › Hormonal Agents › Progesterone and Progestins · Perimenopause and Menopause › Hormone Therapy › Benefits and Risks
Vanadin Seifert-Klauss, Jerilynn C Prior
V Seifert-Klauss, J Prior
PMID 21052538 21052538 DOI 10.4061/2010/845180 10.4061/2010/845180 Seifert-Klauss et al. 2010, Seifert-Klauss 2010